About Us

Real Team.

Real Purpose.

Learn More
Arrow icon

Our StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur Story

Our StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur StoryOur Story

Gradient image
Image

Our Story

Our mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining the potential of high-value GPCR drug targets with the power of state-of-the-art small molecule drug discovery technologies. Septerna’s Native Complex™ Platform is the engine that will make this happen, moving ideas for disease-modifying therapies from possibility to reality.

Septerna has assembled a team that thrives on innovation, combining pioneering GPCR scientists with experienced drug hunters. Our founders have made seminal discoveries that reveal the inner workings of GPCRs and how they control physiology. Our scientists have built upon these unique insights to develop our industrial-scale Native Complex™ Platform.

We are focusing the Native Complex™ Platform on tackling previously difficult-to-drug GPCR targets, and our small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. With an unprecedented level of productivity, we are setting the stage for a new future for GPCR-targeted medicines.

Gradient image
Gradient image
Gradient image

Our TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur Team

Our TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur TeamOur Team

Gradient image

Our Team

Alan Ezekowitz, M.D., D.Phil.

Interim Chief Medical Officer

Alex Kunzle

Protein Sciences

Ali Masoudi, Ph.D.

Protein Sciences

Amer M. Mirza, Ph.D.

Vice President, Disease Biology and Translational Sciences

Ariel Wein, Ph.D.

Protein Sciences

Chia-Hung Tai

Discovery Biology

Chris Heise, Ph.D.

Vice President, Discovery Biology

Daniel Long, D.Phil.

Senior Vice President, Drug Discovery

Dean P. Staus, Ph.D.

Protein Sciences

Dodzie Sogah, Ph.D.

Interim Chief Operating Officer

Elyas Kefela

Operations

Evan Green, Ph.D.

Protein Sciences

George Xu, Ph.D.

Director, Corporate Strategy & Portfolio Development

Jeffrey Finer, M.D., Ph.D.

Interim President & Chief Executive Officer

Jialu Wang, Ph.D.

Protein Sciences

Kathryn Luderman, Ph.D.

Discovery Biology

Kara Halvorsen

Interim Head, Human Resources

Kris Dalmacio

Operations

Matthew Volgraf, Ph.D.

Medicinal Chemistry

Michael Broeker

Operations

Richard Hansen, Ph.D.

Vice President, Technology

Richard van Rijn, Ph.D.

Disease Biology

Ryan Strachan, Ph.D.

Discovery Biology

Uwe Klein, Ph.D.

Senior Vice President, Biological Sciences

Victoria Wu, Ph.D.

Disease Biology

Gradient image

Our Teams

Robert Lefkowitz, M.D.

Duke University, HHMI

Arthur Christopoulos, Ph.D.

Monash University

Patrick Sexton, PhD, DSc

Monash University

Jeffrey Finer, M.D., Ph.D.

Director, Interim CEO
Septerna, Third Rock Ventures

Investors

Join Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our Team

Join Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our TeamJoin Our Team

Join Our Team

Join our growing team of experts

Learn More